Chordoma is a rare tumor characterized by poor prognosis, limited therapeutic options, and a high rate of recurrence. Despite advances in oncology, effective treatments for chordoma remain limited. Resistance to conventional radiotherapy and chemotherapy restricts therapeutic options, and surgical treatment is often challenging due to the tumor’s proximity to critical anatomical structures. Consequently, identifying novel therapeutic targets is essential for improving chordoma diagnosis, treatment strategies, and outcome prediction.
In recent years, the tumor immune microenvironment has emerged as a key area of research for understanding tumor development, recurrence, and therapeutic resistance. Chordomas are known to interact extensively with the immune system. Although eosinophils are recognized for…